advanbiomed.com (ADVB): Utang-utang marang kapitalisasi buku

Logo grafis Advanced Biomed (ADVB)

The history of leverage relative to market capitalization demonstrates the financial stability of Advanced Biomed Inc (ADVB). The business relies on the development of microfluidic systems for rapid oncology analysis with the potential for recurring payments. Development is driven by a synergy of scientists and engineers dedicated to the project's mission. However, the lack of sales and dependence on insurance companies limit pricing power, meaning the current status is 0.08.

Advanced Biomed Inc. (ADVB) - Utang-utang marang nilai buku saka 07.03.2025 nganti 26.10.2026
Barang utama advanbiomed.com

Advanced Biomed Inc (ADVB) is scaling its network of oncology centers through the implementation of early cancer detection technologies. This calculation captures the mathematical proportion of debt to equity, excluding market noise. By analyzing the dynamics of debt obligations relative to balance sheet equity, an investor determines the business's degree of dependence on creditors. An increase in this ratio may indicate either risky leverage or the expansion of laboratories. The stability of this metric confirms the asset's financial resilience.

Karo sapa Advanced Biomed Inc saingan

ONC - Rasio utang marang kapitalisasi buku|Rasio utang marang nilai buku halozyme.com HALO|RVMD: Utang-utang marang kapitalisasi buku|AAPG - Utang marang nilai buku|Utang-utang marang kapitalisasi buku CGON|URGN (UroGen Pharma Corp) - Utang-utang marang nilai buku|BCAX - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik personalis.com (PSNL)|Erasca (ERAS) - Utang marang nilai buku|Rasio utang marang aset resik Delcath Systems Inc (DCTH)|YmAbs - Utang-utang marang kapitalisasi buku|AURA - Utang marang nilai buku|Candel - Utang marang nilai buku|ARAY: Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku CTOR (Citius Oncology, Inc)|Utang-utang marang nilai buku TuHURA|Utang-utang marang kapitalisasi buku TARA|Utang-utang marang kapitalisasi buku fatetherapeutics.com (FATE)|WHWK - Utang-utang marang kapitalisasi buku|TCRX - Rasio utang marang nilai buku|CSBR - Utang marang nilai buku|XBIT - Rasio utang marang kapitalisasi buku|CVM: Utang-utang marang kapitalisasi buku|OSTX (ostherapies.com) - Utang-utang marang kapitalisasi buku|Rasio utang marang kapitalisasi buku Radiopharm Theranostics Limited (RADX)|Rasio utang marang nilai buku Artiva|Utang-utang marang kapitalisasi buku ANL (Adlai Nortye Ltd.)|Utang marang nilai buku Veru Corporation (VERU)|TPST: Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku Xilio Therapeutics Inc XLO|Enochian BioSciences (RENB) - Utang-utang marang kapitalisasi buku|Mural Oncology plc (MURA) - Rasio utang marang nilai buku|Utang marang nilai buku kairospharma.com KAPA|OnKure Therapeutics (OKUR) - Rasio utang marang aset resik|Utang-utang marang kapitalisasi buku CytoMed Therapeutics Ltd|Rasio utang marang kapitalisasi buku Curis Corp|APLM (Apollomics, Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik THAR (Tharimmune Inc)|GNPX: Rasio utang marang kapitalisasi buku|Calidi Biotherapeutics Inc. - Utang-utang marang nilai buku|SBFM: Rasio utang marang kapitalisasi buku|XBIO - Utang marang nilai buku|Utang-utang marang kapitalisasi buku SLRX|Purple Biotech Ltd (PPBT) - Utang-utang marang nilai buku|Utang-utang marang kapitalisasi buku American Oncology Network Inc (AONC)|Rasio utang marang nilai buku BeiGene Ltd (BGNE)|Checkpoint Therapeutics (CKPT) - Utang marang nilai buku|Rasio utang marang aset resik elevationoncology.com (ELEV)|Utang-utang marang kapitalisasi buku ICAD|Ikena Oncology Inc. - Utang-utang marang aset resik|Notable Labs Inc. (NTBL) - Rasio utang marang kapitalisasi buku|VIRX - Rasio utang marang nilai buku|MOR (MorphoSys AG) - Utang-utang marang kapitalisasi buku|nayabiosciences.com (NAYA) - Utang marang nilai buku|AAPGV (Ascentage Pharma) - Utang-utang marang kapitalisasi buku